This is a Phase 1 study of MORAb-202 in participants with solid tumors. This study will be conducted in 2 parts (Part 1 and Part 2). Part 1 will be the dose escalation portion of this study to evaluate dose-limiting toxicity (DLT) and to determine the maximum tolerated dose (MTD) of MORAb-202 in participants with solid tumors. Considering efficacy, safety, and the pharmacokinetic (PK) profile, one dose may be selected from Part 1 for Part 2. Part 2 will comprise cohort expansions to further characterize the safety of MORAb-202 and to evaluate the preliminary efficacy of MORAb-202 in participants with folate receptor alpha (FRA)-positive platinum-resistant ovarian carcinoma and non-small cell lung cancer (NSCLC). The recommended dose for future studies will be determined based on the data from Part 1 and Part 2.
選択基準(Part 2のみ)
(11)以下の基準を満たす測定可能病変を有する患者。
a) RECIST v1.1(付録 2)に基づき,CT又はMRIを用いて,測定可能な病変(非リンパ節の場合は長径が1.0 cm以上,リンパ節の場合は短径が1.5 cm以上)を少なくとも1つ有する。
b) 放射線外照射療法又はラジオ波焼灼等の局所療法を受けた病変を標的病変とする場合は,RECIST v1.1に基づく病勢の進行が認められていること。
(12)組織学的に以下の卵巣癌(原発性腹膜癌及び卵管癌を含む)もしくは組織学的又は細胞学的に以下の非小細胞肺癌と診断された患者。
-コホート1:High grade漿液性腺癌
-コホート2:その他の組織型(粘液性腺癌を除く)
-コホート3:非小細胞肺癌(腺癌)
-コホート4:非小細胞肺癌(腺癌以外)
コホート1又は3の患者は,中央測定機関でのIHC 検査に利用可能な保存腫瘍組織検体(手術検体,切除生検検体又は切開生検検体)を有する場合,FRA陽性であることの事前確認は不要とする(スクリーニング1を必要としない)。ただし、利用可能な保存腫瘍組織検体(手術検体,切除生検検体又は切開生検検体)が無い場合,FRA陽性であることの事前確認を必要とする(スクリーニング1を必要とする)。
コホート2又は4の患者は腫瘍切除検体(手術検体,切除生検検体又は切開生検検体)あるいは腫瘍針生検(可能な限り18G以下)検体を用いて,中央測定機関のIHC検査でFRA陽性であることを確認する必要がある(スクリーニング1を必要とする)。
(13)以下の基準を満たす病変を有する患者。
a. 卵巣癌(原発性腹膜癌及び卵管癌を含む)
-卵巣癌に対する直近の白金製剤を含む化学療法が4サイクル以上であり,かつ白金製剤抵抗性(放射線画像検査により白金製剤投与終了後6ヵ月未満の再発)が認められた患者。
-白金製剤抵抗性と診断された後に0~2レジメンの前治療歴を有する患者。
b. 非小細胞肺癌
-前治療で病勢が進行し,標準療法が存在しない患者及びEGFR,BRAF V600E,ALK又はROSを標的とした分子標的薬の対象とならない患者(分子標的薬治療後に病勢が進行した患者も含む)。
1) Participants who have provided voluntary written consent for participation in this clinical study.
2) Participants to whom the rules for complying with this clinical study have been adequately explained, and who intend to and can comply with those rules.
3) Male or female participants age >= 20 years at the time of informed consent of screening 1 (or screening 2, in case of participants who enter this clinical study from screening 2).
4) Part 1 only: Participants with folate receptor alpha (FRA)-positive solid tumor confirmed by immunohistochemistry (IHC) assay at the central laboratory using their available tumor samples from resected specimen (i.e., surgical or excisional/incisional biopsy samples) or core needle biopsy (<=18-gauge), or subjects with a histological and/or cytological diagnosis of any serous ovarian carcinoma, fallopian tube carcinoma, endometrial carcinoma, or adenocarcinoma of Non-Small Cell Lung Cancer (NSCLC), whose archival resected tumor samples (that is, surgical or excisional/incisional biopsy sample).
5) Part 1 only: At informed consent of screening 2, participants who failed standard therapies, or for which no appropriate treatment is available.
6) Participants with adequate function of major organs within 2 weeks prior to the first administration of the study drug as follows.
1. Hemoglobin >= 9.0 grams per deciliter (g/dL).
2. Neutrophil count >=1.5 * 10^3/microliters (microL).
3. Platelet count >= 10 * 10^4/microL.
4. Total bilirubin <= 1.5 * upper limit of normal (ULN) in the facility.
5. Alanine aminotransferase and aspartate aminotransferase <= 3.0 * ULN (in the case of liver metastases <=5 * ULN) in the facility.
6. Serum creatinine <= 1.5 * ULN in the facility.
7. Albumin >= 3 g/dL.
7) Participants with Performance Status score of 0-1 established by Eastern Cooperative Oncology Group.
8) Participants who are expected to survive for 3 months or longer after the first administration of the study drug.
9) Washout period required from the end of prior treatment to the first administration of the study drug will be as follows
a. Anticancer therapy
- Antibody and other study drugs: > 4 weeks (however, in the case where the half-life of other study drugs is known and 5 * half-lives of that study drug is less than or equal to 4 weeks, participants can be eligible after >= 5 * half-lives of that study drug has passed).
- Prior chemotherapy (except small-molecule targeted therapy), surgical therapy, radiation therapy: >3 weeks.
- Endocrine therapy, immunotherapy except antibody, small-molecule targeted therapy: >2 weeks.
b. Supportive therapies
- Blood/platelet transfusion, hematopoietic stimulating agent including granulocyte colony-stimulating factor formulation: > 2 weeks.
10) Participants whose formalin fixed, paraffin-embedded unstained slides of tumor sample are available for IHC test at central laboratory. If applicable biopsy will be performed by excisional, incisional or needle puncture (<=18-gauge as far as possible).Inclusion Criteria (Part 2 only)
11) Measurable disease meeting the following criteria:
a) At least 1 lesion of >= 1.0 centimeters (cm) in the longest diameter for a non-lymph node or >= 1.5 cm in the short-axis diameter for a lymph node that is measurable according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 using computerized tomography/magnetic resonance imaging.
b) Lesions that have had external beam radiotherapy or locoregional therapies such as radiofrequency ablation must show evidence of progressive disease based on RECIST 1.1 to be deemed a target lesion.
12)Subjects histologically diagnosed with the following ovarian carcinoma (including primary peritoneal carcinoma and fallopian tube carcinoma) or NSCLC. Subjects for Cohort 1 and 3 who have archival resected tumor samples (ie, surgical or excisional/incisional biopsy sample) for IHC assay are not required to be FRA positive at the central laboratory (Screening 1 is not required). Subjects for Cohort 1 and 3 who do not have archival resected tumor samples (ie, surgical or excisional/incisional biopsy sample) are required to be FRA positive at the central laboratory (Screening 1 is required). Subjects for Cohort 2 and 4 are required to be FRA positive confirmed by IHC assay at the central laboratory using their available tumor samples from resected specimen (ie, surgical or excisional/incisional biopsy samples) or core needle biopsy (<=18-gauge as far as possible) (Screening 1 is required).
- Cohort 1: High grade serous adenocarcinoma
- Cohort 2: Other histological types (excluding mucinous adenocarcinoma)
- Cohort 3: NSCLC adenocarcinoma
- Cohort 4: NSCLC non-adenocarcinoma
13)Subjects with the following disease characteristics:
a. Ovarian carcinoma (including primary peritoneal carcinoma and fallopian tube carcinoma):
-Subjects with platinum-resistant disease (defined as progression radiographically within <6 months from completion of last platinum therapy) who have received >4 cycles in last platinum-containing chemotherapy for ovarian carcinoma
- Subjects who have received up to two regimen of chemotherapy after diagnosed as platinum-resistant
b. NSCLC:
- Subjects that have advanced after previous treatment and those for which no alternative standard therapy exist and those who are not indicated for epidermal growth factor receptor (EGFR), BRAF V600E mutation, ALK or ROS-targeted therapy (subjects who have progressed after prior such therapy may be eligible)
1) Medical history of clinically significant cardiovascular impairment:
a) Congestive heart failure greater than or equal to New York Heart Association Class III.
b) Unstable angina pectoris, myocardial infarction or stroke within 6 months before of the first administration of the study drug.
c) Prolongation of corrected QT (QTc) interval to > 480 milliseconds (ms) (Fridericia method).
d) Arrhythmias associated with hemodynamic instability
2) Concomitant systemic infection requiring medical treatment.
3) Participants who test positive for human immunodeficiency virus (HIV antibody).
4) Active viral hepatitis (B or C) (*) as demonstrated by positive serology or requiring treatment.
(*) hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs)/hepatitis B core antibody (HBcAb), and anti-hepatitis C virus (HCV) antibody test. Participants who are anti-HBs/HBcAb (+) without detectable hepatitis B virus (HBV)-deoxyribonucleic acid (DNA)/HCV- ribonucleic acid (RNA) are eligible.5) Effusion requiring drainage continually.
6) Participants whose toxicity of previous treatment has not recovered to Grade 1 or lower (except for alopecia and hemoglobin).
7) Participants who have received a previous monoclonal antibody therapy and have evidence of an immune or allergic serious reaction.
8) Participants who had previous treatment with other folate receptor targeting agents.
9) Participants who have medical history of discontinuing prior eribulin due to toxicity.
10) Has an active pneumonitis/interstitial lung disease (ILD), a history of pneumonitis/ILD received radiotherapy to lung field within 12 months before the first dose of study intervention, or current clinically relevant lung disease (example, Chronic Obstructive Pulmonary Disease).
11) Other active malignancy (except for definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix) within the past 24 months prior to the first administration of the study drug.12) Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin or human chorionic gonadotropin). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 3 days before the first administration of the study drug (breastfeeding participants are not eligible even if they discontinue breastfeeding).
13) Women of childbearing potential or man of impregnate potential who don't agree that both the participant and his/her partner will use a medically effective method for contraception (as below) during the study and after study drug discontinuation (male; 90 days, female; 60 days).
Note: Condom*, contraceptive sponge**, foam**, jelly**, diaphragm*, intrauterine device*, or use of oral contraception* from at least 4 weeks before starting the study treatment (*Approved drugs or certified medical devices in Japan, **Non-approved drugs or certified medical devices in Japan).14) Known intolerance to the study drug or any of the excipients.
15) Any medical or other condition that in the opinion of the investigator(s) would preclude the subject's participation in the study.
16) Scheduled for surgery during the study.
17) Diagnosed with meningeal carcinomatosis.
18) Participants with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study. Any signs (e.g., radiologic) or symptoms of brain metastases must be stable for at least 4 weeks before starting study treatment.
19) Use of illegal recreational drugs.
Exclusion Criteria (Part 2 only)
20) Previous treatment with eribulin
21) Participants histologically diagnosed with mucinous ovarian carcinoma
22) (Ovarian carcinoma only) Participants who progressed during the preceding platinum-containing chemotherapy (for platinum refractory)
investigational material(s)
Generic name etc : MORAb-202
INN of investigational material : -
Therapeutic category code : 429 Other antitumor agents
Dosage and Administration for Investigational material : Part 1 (Dose-escalation) and Part 2 (Treatment Phase): MORAb-202 will be administered every 3 weeks,
control material(s)
Generic name etc : -
INN of investigational material : -
Therapeutic category code :
Dosage and Administration for Investigational material : -
safety
Number of participants with dose-limiting toxicities (DLTs)
-infusion reactions
-Part 1 and Part 2: Number of participants with adverse events (AEs), adverse events of interest (AEIs), and serious adverse events (SAEs)
-Number of participants with any clinically significant vital sign value
-Change from Baseline in body weight
-Number of participants with any clinically significant 12-lead electrocardiogram (ECG) value
-Change from Baseline in the performance status (PS) score established by the Eastern Cooperative Oncology Group (ECOG)
-Change from Baseline in physical examinations
safety
efficacy
pharmacokinetics
-Part 1: Maximum Tolerated Dose (MTD) of MORAb-202
-Part 1 and Part 2: Maximum observed serum concentration (Cmax) of MORAb-202
-Part 1 and Part 2: Plasma concentration of free eribulin
-Part 1 and Part 2: Maximum serum concentration of total antibody
-Recommended dose (RD) of MORAb-202 for future studies
-Part 1 and Part 2: Overall response rate (ORR) ,Disease control rate (DCR), Clinical benefit rate (CBR)
-Part 2: Duration of Response (DOR),Progression-free survival (PFS) ,Overall Survival (OS)
(2)試験等に用いる医薬品等の概要
医薬品
medicine
MORAb-202
MORAb-202
-
-
429 その他の腫瘍用薬
429 Other antitumor agents
Part 1 及びPart 2 ともにMORAb-202 を3 週間ごとに1 回,静脈内点滴投与する。
Part 1 (Dose-escalation) and Part 2 (Treatment Phase): MORAb-202 will be administered every 3 weeks,
関連ID名称 : Study ID Number
関連ID番号 : MORAb-202-J081-101
関連ID名称 : ClinicalTrials.gov NCT Number
関連ID番号 : NCT03386942
Related ID Name : Study ID Number
Related ID number : MORAb-202-J081-101
Related ID Name : ClinicalTrials gov. NCT Number
Related ID number : NCT03386942